301 related articles for article (PubMed ID: 33551797)
1. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y
Zhang Y; Shi XJ; Peng WX; Han JL; Lin BD; Zhang R; Zhang YN; Yan JL; Wei JJ; Wang YF; Chen SW; Nan N; Fang ZW; Zeng Y; Lin Y
Front Pharmacol; 2020; 11():582929. PubMed ID: 33551797
[No Abstract] [Full Text] [Related]
2. Clinical Outcomes and Sustainability of Using
Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
[TBL] [Abstract][Full Text] [Related]
3. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
4. The contribution of genotype-guided selection of P2Y
Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T
Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China.
Zhang Y; Zhang Y; Shi X; Lin B; Han J; Wang Y; Yan J; Peng W; Li W; Zheng Z; Lin Y
Thromb Haemost; 2022 May; 122(5):842-852. PubMed ID: 34428831
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of
Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J
Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282
[No Abstract] [Full Text] [Related]
8. Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention.
Zhang D; Li P; Qiu M; Liang Z; He J; Li Y; Han Y
Atherosclerosis; 2024 Mar; 390():117395. PubMed ID: 38114408
[TBL] [Abstract][Full Text] [Related]
9. Risk of major adverse cardiovascular events of
Biswas M; Kali MSK; Biswas TK; Ibrahim B
Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
[TBL] [Abstract][Full Text] [Related]
11. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
12.
Beitelshees AL; Thomas CD; Empey PE; Stouffer GA; Angiolillo DJ; Franchi F; Tuteja S; Limdi NA; Lee JC; Duarte JD; Kreutz RP; Skaar TC; Coons JC; Giri J; McDonough CW; Rowland R; Stevenson JM; Thai T; Vesely MR; Wellen JT; Johnson JA; Winterstein AG; Cavallari LH; Lee CR;
J Am Heart Assoc; 2022 Feb; 11(4):e024159. PubMed ID: 35156424
[TBL] [Abstract][Full Text] [Related]
13. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R
Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117
[TBL] [Abstract][Full Text] [Related]
14. Genetic-Guided Oral P2Y
Ingraham BS; Farkouh ME; Lennon RJ; So D; Goodman SG; Geller N; Bae JH; Jeong MH; Baudhuin LM; Mathew V; Bell MR; Lerman A; Fu YP; Hasan A; Iturriaga E; Tanguay JF; Welsh RC; Rosenberg Y; Bailey K; Rihal C; Pereira NL
JACC Cardiovasc Interv; 2023 Apr; 16(7):816-825. PubMed ID: 37045502
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Clopidogrel vs Alternative P2Y
Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Ortega-Paz L; Gong Y; Kerensky RA; Kulick N; McDonough CW; Nguyen AB; Wang Y; Winget M; Yang WE; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Lee CR; Cavallari LH
J Am Coll Cardiol; 2024 Apr; 83(15):1370-1381. PubMed ID: 38599713
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Peng W; Zhang Y; Li X; Lin Y
J Cardiovasc Pharmacol; 2023 Feb; 81(2):134-140. PubMed ID: 36410041
[TBL] [Abstract][Full Text] [Related]
17. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
[TBL] [Abstract][Full Text] [Related]
18. The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.
Akkaif MA; Daud NAA; Noor DAM; Sha'aban A; Kader MASA; Ibrahim B
Cardiovasc Drugs Ther; 2024 Jan; ():. PubMed ID: 38224415
[TBL] [Abstract][Full Text] [Related]
19. Effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention.
Wood B; Lee CR; Mulrenin IR; Gower MN; Rossi JS; Weck KE; Stouffer GA
Pharmacotherapy; 2021 Dec; 41(12):970-977. PubMed ID: 34242414
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease.
Cheng Y; Sun Y; Zhang D; Ma X; Liu C; Hu C; Sun T; Zhao Z; Liu X; Zhou Y
Front Cardiovasc Med; 2023; 10():1105001. PubMed ID: 36760562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
